Early Triple Vasopressors Accelerate Renin and Lactate Clearance in Septic Shock
TRICYCLE is the first randomized trial to test simultaneous angiotensin II, vasopressin, and norepinephrine at the onset of catecholamine-refractory septic shock, offering ICU pharmacists early physiologic signal data before any mortality verdict.
📅 Journal publication: Sep 7, 2026·Last updated: Oct 6, 2026
angiotensin IIvasopressinnorepinephrinevasopressorsseptic shockreninlactateSOFAtachyarrhythmiaphase II RCThemodynamicsTRICYCLESurviving Sepsis CampaignCritical Care / ICU
Background Information
Early multimodal vasopressor therapy shows promise in septic shock management.
Septic shock requires prompt management, and finding effective vasopressor strategies can improve patient outcomes and reduce ICU mortality. Early multimodal vasopressor therapy led to faster declines in plasma renin and lactate concentrations and lower incidences of tachyarrhythmias compared to traditional therapy. While physiological benefits were observed, the study was not powered to demonstrate differences in mortality, indicating the need for larger trials to evaluate patient-centered outcomes. Early multimodal vasopressor therapy shows promising physiological benefits in septic shock management.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Kalamar Ž, Landoni G, Gorenjak M, Cestar I, Fluher J, Horvat M, Jerenec K, Kit B, Marinšek M, Puklavec N, Svenšek F, Radonić R, Šundalić S, Brajković AV, Vujević A, Erjavc N, Petek D, Košir AS, Homšak E, Knehtl MC, Markota A
Citation:Kalamar Ž, Landoni G, Gorenjak M, et al. Early multimodal vasopressor strategy in septic shock: results of the TRICYCLE randomized controlled trial. Critical care (London, England). 2026;30(1). doi:10.1186/s13054-026-06323-z